ClinicalTrials.gg
CompletedNCT01513551Updated Dec 13, 2018Results posted

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

A Phase 2 interventional study of Pneumococcal Conjugate Vaccine (V114) and PNEUMOVAX® 23 in Pneumococcal Infections, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
692
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Pneumococcal Infections by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Pneumococcal Infections · Merck & Co., Inc.

Enrollment
18th of 43
692 · median 518
Started
2012
the only one that year
Phase 2
5 of 43
none open now
Registered
7th of 43
by date

Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 18th largest by enrollment, is the only one that started in 2012, is one of 5 in phase 2, and was the 7th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 43 studies in Pneumococcal Infections by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Pneumococcal Infections by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of the study is to see if an investigational vaccine for Streptococcus pneumonia disease (V114) has comparable safety, tolerability, and antibody response to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®) when administered to healthy adults 50 years of age or older.

The primary hypothesis is the serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) as measured by the pneumococcal electrochemiluminescence (Pn ECL) assay at one month postvaccination in subjects who receive V114 will be noninferior to those measured in subjects who receive PNEUMOVAX® 23.

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • Pneumococcal vaccines
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Without fever for 72 hours prior to vaccination

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of any pneumococcal polysaccharide vaccine or any pneumococcal conjugate vaccine
  • Known or suspected to be
  • Functional or anatomic asplenia
  • History of disease
  • Evidence of dementia or cognitive impairment
  • Use of any immunosuppressive therapy
  • Received a licensed non- administered within the 14 days prior to receipt of study vaccine or scheduled to receive any other licensed vaccine within 30 days following receipt of study vaccine
  • Received a licensed live virus vaccine within 30 days prior of receipt of study vaccine or is scheduled to receive any other licensed vaccine within 30 days of receipt of study vaccine
  • Received any vaccine containing diphtheria toxoid within 6 months prior to receipt of study vaccine
  • Received a blood transfusion or blood products within the 6 months before receipt of study vaccine or scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine
  • History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease
  • Received antibiotic therapy for any acute illness within 72 hours before receipt of study vaccine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
692 participants (actual)

Study arms

  • Experimental
    V114

    Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.

    Biological: Pneumococcal Conjugate Vaccine (V114)

  • Active comparator
    PNEUMOVAX® 23

    Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.

    Biological: PNEUMOVAX® 23

  • Active comparator
    PREVNAR 13®

    Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.

    Biological: PREVNAR 13®

Interventions

  • 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.

  • BiologicalPNEUMOVAX® 23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.

  • BiologicalPREVNAR 13®

    13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Adverse Event

    An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.

    Time frame: All AEs: up to 14 days after vaccination; Serious Adverse Events (SAEs): up to 6 months after vaccination

  2. Percentage of Participants With an Injection-site Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups

    Injection-site AEs reported by \>=2% of participants in one or more vaccination groups were assessed.

    Time frame: Up to Day 14 postvaccination

  3. Percentage of Participants With a Systemic Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups

    Systemic AEs reported by \>=2% of participants in one or more vaccination groups were assessed.

    Time frame: Up to Day 14 postvaccination

  4. Percentage of Participants With a Serious Adverse Event

    A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.

    Time frame: Up to 6 months postvaccination

  5. Percentage of Participants With a Vaccine-related Serious Adverse Event

    A SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs deemed by the investigator to be possibly, probably, or definitely related to study vaccine were reported.

    Time frame: Up to 6 months postvaccination

  6. Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies

    Pneumococcal serotype-specific IgG was measured in serum using an electrochemiluminescence (ECL) assay.

    Time frame: One month postvaccination

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibodies

    OPA for the serotypes contained in V114 was determined using a Multiplex Opsonophagocytic Assay (MOPA-4)

    Time frame: One month postvaccination

07

Results

Posted Dec 13, 2018

Participant flow

This trial was conducted at 25 trial centers: 10 in the United States; 2 in Canada; 2 in Denmark; 2 in Israel; 2 in Norway, 3 in Poland, 2 in Spain and 2 in Sweden.

Participant flow — Overall Study
MilestoneV114PNEUMOVAX® 23PREVNAR 13®
Started230231231
Vaccinated230231230
Completed226225226
Not completed465
Withdrew: Death010
Withdrew: Lost to follow-up352
Withdrew: Withdrawal by subject102
Withdrew: Randomized but not vaccinated001

Outcome measures

PrimaryPercentage of Participants With an Adverse Event

An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.

Time frame:
All AEs: up to 14 days after vaccination; Serious Adverse Events (SAEs): up to 6 months after vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With an Adverse Event
Percentage of ParticipantsV114PNEUMOVAX® 23PREVNAR 13®
Percentage of Participants With an Adverse Event75.168.365.7
Statistical analysis
  • V114 vs PNEUMOVAX® 23 · Miettinen & Nurminen · Risk difference (rd): 6.8 · 95% CI -1.4 to 15.0
  • V114 vs PREVNAR 13® · Miettinen & Nurminen · Risk difference (rd): 9.5 · 95% CI 1.1 to 17.7
PrimaryPercentage of Participants With an Injection-site Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups

Injection-site AEs reported by \>=2% of participants in one or more vaccination groups were assessed.

Time frame:
Up to Day 14 postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With an Injection-site Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups
Percentage of ParticipantsV114PNEUMOVAX® 23PREVNAR 13®
Injection site erythema14.814.813.0
Injection site induration14.810.412.6
Injection site pain60.351.353.0
Injection site pruritus3.11.32.2
Injection site swelling20.110.918.3
Injection site warmth0.90.02.2
PrimaryPercentage of Participants With a Systemic Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups

Systemic AEs reported by \>=2% of participants in one or more vaccination groups were assessed.

Time frame:
Up to Day 14 postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Systemic Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups
Percentage of ParticipantsV114PNEUMOVAX® 23PREVNAR 13®
Percentage of Participants With a Systemic Adverse Event Reported With >=2% Incidence in One or More Vaccination Groups48.543.945.6
PrimaryPercentage of Participants With a Serious Adverse Event

A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.

Time frame:
Up to 6 months postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Serious Adverse Event
Percentage of ParticipantsV114PNEUMOVAX® 23PREVNAR 13®
Percentage of Participants With a Serious Adverse Event1.73.02.2
PrimaryPercentage of Participants With a Vaccine-related Serious Adverse Event

A SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs deemed by the investigator to be possibly, probably, or definitely related to study vaccine were reported.

Time frame:
Up to 6 months postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Vaccine-related Serious Adverse Event
Percentage of ParticipantsV114PNEUMOVAX® 23PREVNAR 13®
Percentage of Participants With a Vaccine-related Serious Adverse Event0.00.00.0
PrimaryGeometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies

Pneumococcal serotype-specific IgG was measured in serum using an electrochemiluminescence (ECL) assay.

Time frame:
One month postvaccination
Reported as:
Geometric mean · µg/mL
Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies
µg/mLV114PNEUMOVAX® 23PREVNAR 13®
Serotype 13.76 (3.05 to 4.65)3.30 (2.68 to 4.07)3.12 (2.54 to 3.82)
Serotype 31.13 (0.96 to 1.35)0.57 (0.47 to 0.68)0.56 (0.47 to 0.66)
Serotype 41.96 (1.59 to 2.41)1.03 (0.83 to 1.27)2.09 (1.70 to 2.56)
Serotype 53.99 (3.23 to 4.92)2.70 (2.21 to 3.30)2.76 (2.21 to 3.44)
Serotype 6A4.88 (3.73 to 6.39)1.14 (0.90 to 1.43)4.86 (3.86 to 6.13)
Serotype 6B5.43 (4.11 to 7.17)2.01 (1.58 to 2.57)2.81 (2.19 to 3.62)
Serotype 7F4.59 (3.72 to 5.66)3.74 (3.00 to 4.65)6.06 (4.91 to 7.48)
Serotype 9V4.05 (3.32 to 4.93)2.72 (2.21 to 3.36)3.41 (2.77 to 4.20)
Serotype 148.56 (6.86 to 10.69)8.13 (6.38 to 10.36)8.90 (7.08 to 11.18)
Serotype 18C8.00 (6.62 to 9.68)4.66 (3.73 to 5.82)6.83 (5.68 to 8.20)
Serotype 19A9.36 (7.66 to 11.44)6.99 (5.67 to 8.61)11.36 (9.28 to 13.92)
Serotype 19F3.35 (2.67 to 4.21)4.17 (3.32 to 5.24)4.80 (3.81 to 6.04)
Serotype 22F5.21 (4.25 to 6.39)1.98 (1.61 to 2.44)0.38 (0.32 to 0.44)
Serotype 23F5.55 (4.33 to 7.12)1.82 (1.44 to 2.30)3.41 (2.62 to 4.43)
Serotype 33F11.56 (9.27 to 14.40)8.26 (6.52 to 10.47)0.85 (0.70 to 1.03)
SecondaryGeometric Mean Titer (GMT) of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibodies

OPA for the serotypes contained in V114 was determined using a Multiplex Opsonophagocytic Assay (MOPA-4)

Time frame:
One month postvaccination
Reported as:
Geometric mean · Titer
Geometric Mean Titer (GMT) of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibodies
TiterV114PNEUMOVAX® 23PREVNAR 13®
Serotype 1208.03 (156.36 to 276.78)117.87 (87.11 to 159.49)115.75 (85.72 to 156.31)
Serotype 3595.16 (498.23 to 710.95)313.83 (256.64 to 383.76)256.76 (212.08 to 310.85)
Serotype 42875.79 (2215.61 to 3732.69)1099.88 (804.01 to 1504.63)3001.63 (2380.57 to 3784.72)
Serotype 5712.21 (537.78 to 943.22)288.41 (210.03 to 396.06)372.35 (271.76 to 510.19)
Serotype 6A4216.34 (2977.07 to 5971.49)490.60 (325.94 to 738.44)5251.47 (4114.87 to 6702.00)
Serotype 6B6469.99 (4775.27 to 8766.16)1630.20 (1174.34 to 2263.03)4207.86 (3212.46 to 5511.70)
Serotype 7F5148.66 (4170.62 to 6356.06)3665.62 (2722.58 to 4935.30)7816.74 (6358.89 to 9608.81)
Serotype 9V3024.34 (2338.72 to 3910.96)1674.44 (1252.72 to 2238.12)2471.10 (1882.58 to 3243.60)
Serotype 144352.27 (3374.62 to 5613.15)3572.27 (2667.12 to 4784.61)4478.38 (3647.04 to 5499.22)
Serotype 18C4631.86 (3730.53 to 5750.96)2438.57 (1839.33 to 3233.04)3358.41 (2665.75 to 4231.06)
Serotype 19A3391.18 (2755.18 to 4174.00)2682.65 (2095.62 to 3434.12)4186.28 (3421.20 to 5122.46)
Serotype 19F1201.17 (906.20 to 1592.15)1581.60 (1211.55 to 2064.67)1946.04 (1547.41 to 2447.35)
Serotype 22F8329.52 (6542.87 to 10604.06)4382.78 (3359.60 to 5717.58)57.45 (37.29 to 88.50)
Serotype 23F2217.18 (1588.99 to 3093.71)378.41 (262.42 to 545.67)1197.80 (836.80 to 1714.53)
Serotype 33F31116.90 (24612.69 to 39339.94)27560.15 (21471.19 to 35375.88)3129.94 (2441.58 to 4012.38)

Adverse events

Collected over Up to 6 months postvaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V1140/229 (0%)4/229 (1.7%)167/229 (72.9%)
PNEUMOVAX® 231/230 (0.4%)7/230 (3%)149/230 (64.8%)
PREVNAR 13®0/230 (0%)5/230 (2.2%)141/230 (61.3%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventV114PNEUMOVAX® 23PREVNAR 13®
Coronary artery occlusionCardiac disorders1/2290/2300/230
AppendicitisInfections and infestations1/2291/2300/230
Anal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2290/2300/230
AnxietyPsychiatric disorders1/2290/2300/230
Cardiac failureCardiac disorders0/2291/2300/230
Myocardial infarctionCardiac disorders0/2291/2300/230
VertigoEar and labyrinth disorders0/2291/2301/230
Gastrointestinal disorderGastrointestinal disorders0/2291/2300/230
DeathGeneral disorders0/2291/2300/230
CholecystitisHepatobiliary disorders0/2290/2301/230
Most frequent other events
Most frequent other events
EventV114PNEUMOVAX® 23PREVNAR 13®
Injection site painGeneral disorders138/229118/230122/230
MyalgiaMusculoskeletal and connective tissue disorders69/22960/23050/230
FatigueGeneral disorders57/22963/23055/230
Injection site swellingGeneral disorders46/22925/23042/230
HeadacheNervous system disorders40/22941/23042/230
ArthralgiaMusculoskeletal and connective tissue disorders41/22926/23029/230
Injection site erythemaGeneral disorders34/22934/23030/230
Injection site indurationGeneral disorders34/22924/23029/230

Baseline characteristics

The baseline analysis population consisted of all randomized participants who received study vaccine.

Age, Customized
Age, Customized(Participants)V114PNEUMOVAX® 23PREVNAR 13®Total
50 to 64 years798080239
65 to 74 years757674225
>= 75 years767576227
Sex: Female, Male
Sex: Female, Male(Participants)V114PNEUMOVAX® 23PREVNAR 13®Total
Female122123122367
Male108108108324
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)V114PNEUMOVAX® 23PREVNAR 13®Total
Hispanic or Latino14201448
Not Hispanic or Latino216211215642
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)V114PNEUMOVAX® 23PREVNAR 13®Total
American Indian or Alaska Native0011
Asian56314
Native Hawaiian or Other Pacific Islander0022
Black or African American1061228
White212217212641
More than one race3205
Unknown or Not Reported0000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, Hartzel J, Marchese RD, Stek JE, Abeygunawardana C, Musey LK. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults >/=50 years of age. Vaccine. 2018 Oct 29;36(45):6875-6882. doi: 10.1016/j.vaccine.2018.03.012. Epub 2018 Mar 17. PubMed 29559167 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Feb 2013, 11 months.

Results were first posted in Dec 2018, 5 years 9 months after primary completion.

Of 23 phase 2 interventional studies under Pneumococcal Infections, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2011
First posted
Jan 20, 2012
StartActual
Mar 13, 2012
Primary completionActual
Feb 15, 2013
CompletionActual
Feb 15, 2013
Results first posted
Dec 13, 2018
Last update
Dec 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01513551
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Mar 13, 2012
Primary completion
Feb 15, 2013
Completion
Feb 15, 2013
Results posted
Dec 13, 2018
Last update
Dec 13, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal Conjugate Vaccine

Start the discussion